Brief: Akoustis Technologies Q3 Basic EPS USD -0.26
13/05/2024 12:30
May 13 (Reuters) - Akoustis Technologies Q3 pretax profit USD -23.306 million. * Q3 net income USD -23.308 million * Q3 operating expenses USD 22.957 million * Q3 gross profit USD 349 thousand * Q3 operating income USD -22.608 million * Q3 revenue USD 7.51 million vs. IBES estimate USD 8.55 million
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut